Quality of life in ovarian cancer survivors
Phase 2
- Conditions
- Health Condition 1: null- Histologically proven ovarian cancer survivors who were diagnosed at least two years back and are on their regular follow-up
- Registration Number
- CTRI/2017/05/008591
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
1.All Ovarian cancer patients with histological proof of malignancy
2.Initial diagnosis two years back
Exclusion Criteria
1.Residual/ recurrent disease at present
2.Wide spread metastatic disease at initial presentation
3.Previous history of malignancy other than ovarian primary
4.Any other serious illness & or major organ dysfunction
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the Quality of Life in long term ovarian cancer survivors <br/ ><br> <br/ ><br>Timepoint: at least 2 years after diagnosis
- Secondary Outcome Measures
Name Time Method To identify the factors related to poor quality of lifeTimepoint: at least 2 years after diagnosis
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms influence quality of life in long-term ovarian cancer survivors?
How does the quality of life in ovarian cancer survivors compare to standard-of-care treatment outcomes?
Are there specific biomarkers associated with improved quality of life in histologically confirmed ovarian cancer survivors?
What adverse events are commonly reported in ovarian cancer survivorship studies and how are they managed?
What combination therapies or related compounds show promise in enhancing quality of life for ovarian cancer patients post-treatment?